HomeAI · summaries
Storia in 2 fonti
Targeted Combo Boosts PFS in BRAF-Mutant Metastatic Colorectal Cancer
Adding encorafenib and cetuximab to chemotherapy backbone also prolonged overall survival
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
Frontline Targeted Therapies Plus R-CHOP Boosts PFS in High-Risk B-Cell Lymphomas
Add-on tafasitamab and lenalidomide did not negatively impact chemotherapy backbone
- ·
morningstar.com
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
- ·
Targeted Combo Boosts PFS in BRAF-Mutant Metastatic Colorectal Cancer
Adding encorafenib and cetuximab to chemotherapy backbone also prolonged overall survival
- ·
Adding Immunotherapy-Based Combo Boosts PFS in Unresectable Liver Cancer
But is the higher incidence of grade 3/4 adverse events 'a worthwhile price to pay?' expert asks